arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

OMEROS CORP

OMER
$17.06 ▼ -1.13 (-6.21%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

OMEROS CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.2B
Dividend Yield —
Revenue Growth None
Op. Margin 0.3% ↗
ROIC -0.1% ↘
FCF / Share $0.06 ↗
Trailing P/E 94.8x
Price / Book —
FCF Yield 0.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$28.53M
↑ +188.4% —
Net Income Profit after all expenses
$56.06M
— 0.0% —
Operating Margin Operating profit as % of sales
0.3%
↑ +100.1% —
FCF / Share Free cash flow per share
$0.06
↑ +128.2% —
Long-Term Debt Long-term obligations
$87.90M
↓ -43.3% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
49
Financial Health ↑
70
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters